Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
Authors
Thatcher, NickCerny, T
Stout, Ronald
Anderson, Heather
Barber, Philip V
Wolstenholme, R J
Barnes, P
Deiraniya, A
Affiliation
CRC Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, United Kingdom.Issue Date
1987-11-15
Metadata
Show full item recordAbstract
One hundred sixty-three patients with small cell lung cancer were treated with six courses, at 3-week intervals, of ifosfamide (5 g/m2) with mesna and etoposide. Thoracic radiotherapy was delivered to the limited stage (LS) patients. The complete response rate (CR, determined clinically and radiologically) was 76% for the 78 LS patients with a further 14% partial response (PR). The majority of the CRs were confirmed on a follow-up bronchoscopy. The CR rate was 27% for extensive stage (ES) patients with another 38% undergoing a partial response. The median survival for LS patients was 11 months, (16 months for CR confirmed by rebronchoscopy) and 8 months for ES patients. The 2-year actuarial survival for LS patients is 27%, follow-up ranges from 12 months to 30 months with a median of 22 months. Toxicity was not severe for the patient population, of whom only 20% had a good performance status before chemotherapy. Parental antibiotics were required on 4% of all 844 chemotherapy courses and 12% of courses were delayed due to side effects. The majority of responses occurred within the first two courses of chemotherapy and there was a corresponding improvement in the patients' symptoms and performance status. The regimen produced rapid tumor response with corresponding improvement in symptoms without marked toxicity and allowed further treatment development.Citation
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. 1987, 60 (10):2382-7 CancerJournal
CancerPubMed ID
2822217Type
ArticleLanguage
enISSN
0008-543XCollections
Related articles
- Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
- Authors: Smith IE, Perren TJ, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, Ford HT
- Issue date: 1990 May
- Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
- Authors: Prendiville J, Radford J, Thatcher N, Steward W, Ranson M, Burt P, Stout R
- Issue date: 1991 Aug
- Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
- Authors: Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S
- Issue date: 1987 Dec
- Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
- Authors: Thatcher N, Lind M, Stout R, Payne C, Carroll KB, Campbell C, Moussalli H
- Issue date: 1989 Jul
- The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
- Authors: Cantwell BM, Bozzino JM, Corris P, Harris AL
- Issue date: 1988 Feb